A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
National Institute of Allergy and Infectious Diseases (NIAID)
To evaluate the effects of three preparations of low-dose oral interferon alpha (i.e.,
Alferon LDO, Veldona, and Ferimmune) on HIV symptoms in HIV-infected patients. To evaluate
differences in response to oral interferon alpha according to gender, race/ethnicity, and
use of antiretrovirals.
Previous or ongoing clinical trials to test the efficacy of low-dose oral interferon alpha
have produced different results, and it is not clear whether the differences were due to the
interferon alpha products used or to problems in the study design. Therefore, three
preparations will be compared to evaluate their potential efficacies.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.